The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd

CTL/SAST/26-27/01328 August 18, 2026 BSE Limited National Stock Exchange of India Limited – Phiroze Jeejeebhoy Towers Corporate Office Dalal Street, Exchange Plaza, C-1, Block G, Mumbai- 400001 Bandra Kurla Complex, Bandra (East), Email: Mumbai – 400051 corp.relations@bseindia.com Email: takeover@nse.co.in Company Name Thyrocare Technologies Ltd D/37-1, TTC Industrial Area, MIDC Turbhe, Navi Mumbai, Maharashtra, 400703 Email: compliance@thyrocare.com Pledgor Name Docon Technologies Private Limited Dear Sir/Madam, Sub: Disclosure pursuant to Regulation 29 (2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 in relation to release on pledge of equity shares of Thyrocare Technologies Ltd Pursuant to the disclosure required to be made under Regulation 29 (2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, please find attached the disclosure in respect of the release on pledge of equity shares of Thyrocare Technologies Ltd (“Target Company”) by Catalyst Trusteeship Limited in the capacity of Debenture Trustee for the benefit of Debenture holders. For Catalyst Trusteeship Limited Authorised Signatory Name: Deesha Srikkanth Designation: Senior Vice President Place: Mumbai Date: August 18, 2026 Disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 Thyrocare Technologies Limited Name of the Target Company (TC) Catalyst Trusteeship Limited acting as Debenture Trustee on Name(s) of the acquirer and Persons Acting in Concert behalf of Debenture Holders of API Holdings Limited (PAC) with the acquirer Whether the acquirer belongs to Promoter/Promoter group BSE Limited Name(s) of the Stock Exchange(s) where the shares of National Stock Exchange of India Limited TC are Listed Number % w.r.t. total % w.r.t. total share/voting diluted Details of the Acquisition as follows capital wherever share/voting applicable (*) capital of the TC (**) Before the releaseunder consideration, holding of: Nil Nil Nil a) Shares carrying voting rights b) Shares in the nature of encumbrance (pledge/ 7,94,69,696 49.93 49.78 lien/ non-disposal undertaking/ others) Nil Nil c) Voting rights (VR) otherwise than by shares d) Warrants/convertible securities/any other Nil Nil instrument that entitles the acquirer to receive shares carrying voting rights in the T C (specify holding in each category) e) Total (a+b+c+d) 7,94,69,696 49.93 49.78 Details of acquisition/release: Nil Nil Nil a) Shares carrying voting rights acquired/sold b) VRs acquired /sold otherwise than by shares Nil Nil Nil c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive Nil Nil Nil shares carrying voting rights in the TC (specify holding in each category) acquired/sold d) Shares in nature of encumbrance (release/pledge 7,94,69,696 49.93 49.78 / lien / non-disposal undertaking / others) e) Total (a+b+c+/-d) 7,94,69,696 49.93 49.78 After the release /sale, holding of: a) Shares carrying voting rights NIL NIL NIL b) Shares encumbered with the acquirer Nil Nil Nil c) VRs otherwise than by shares Nil Nil Nil d) Warrants/convertible securities/any other instrument Nil Nil Nil that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition e) Total (a+b+c+d) NIL NIL NIL Release of pledge on 7,94,69,696 equity Mode of release/ acquisition / sale (e.g. open market / off- Shares of Thyrocare Technologies Limited by market / public issue / rights issue / preferential allotment / inter-se transfer etc). Catalyst Trusteeship Limited, acting as Debenture Trustee, upon the full repayment and redemption of the aforesaid Non- Convertible Debentures, the pledge created by Docon Technologies Private Limited over 7,94,69,696 equity share of Thyrocare in favour of Catalyst Trusteeship Limited, acting as the Debenture Trustee, was fully released. August 17, 2026 Date of acquisition / Release of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable 15,91,65,315 Equity shares having face value Equity share capital / total voting capital of the TC before the of Rs. 10 each said acquisition / sale Total equity share capital of the Target Equity share capital/ total voting capital of the TC after the Company: 15,91,65,315 equity shares of ₹10 said acquisition / sale each. 15,96,30,252 equity shares having face value of Total diluted share/voting capital of the TC after the said Rs. 10 each acquisition (*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement. (**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC. Signature of the acquirer: For Catalyst Trusteeship Limited Authorised Signatory Name: Deesha Srikkanth Designation: Senior Vice President Place: Mumbai Date: August 18, 2026